McSorley, L. M. http://orcid.org/0000-0002-3076-797X
Tharmabala, M.
Al Rahbi, F.
McSorley, K.
Chew, S.
Evoy, D.
Geraghty, J. G.
Prichard, R. S.
Rothwell, J.
McCartan, D. P.
McDermott, E. W.
Keane, M.
Kennedy, M. J.
O’Reilly, S.
Millen, S. J.
Crown, J. P.
Smyth, L. M.
Kelly, C. M.
Quinn, C. M.
Walshe, J. M.
Article History
Received: 18 November 2020
Accepted: 23 March 2021
First Online: 9 April 2021
Declarations
:
: SJ Millen is an employee of Exact Sciences and provided assistance with budget impact calculations. LM Smyth has the following disclosures: Employment: Loxo Oncology at Lilly; Stock and Other Ownership Interests: Lilly; Honoraria: AstraZeneca, Pfizer, Roche/Genentech; Consulting or Advisory Role: AstraZeneca, Roche/Genentech, Loxo Oncology at Lilly, Pfizer, Novartis; Research Funding: AstraZeneca, Roche/Genentech, Puma Biotechnology; Travel, Accommodations, Expenses: Pfizer, Roche/Genentech, Puma Biotechnology. All remaining authors have declared no conflict of interest.
: This is a retrospective observational study of data obtained for clinical purposes. Ethical approval was not required. The study is registered with and approved by the Clinical Audit Committee at St Vincent’s University Hospital, Dublin 4, Ireland. This research was conducted in accordance with the 1964 Helsinki Declaration and its later amendments, and national and institutional research standards.